Concepedia

Publication | Open Access

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

DOIFull Paper Access

221

Citations

31

References

2023

Year

Peter Rossing, Florian M.M. Baeres, George L. Bakris, Heidrun Bosch‐Traberg, Mette Gislum, Stephen Gough, Thomas Idorn, Jack Lawson, Kenneth W. Mahaffey, Johannes F.E. Mann,
Nephrology Dialysis Transplantation

Abstract

FLOW will evaluate the effect of semaglutide on kidney outcomes in participants with CKD and T2D, and is expected to be completed in late 2024.

References

YearCitations

Page 1